Purchase this article with an account.
Enrico Peiretti, CLAUDIO IOVINO, Rita Serra, Giulia Caminiti; Follow-up of patients with PCV in CSCR treated with PDT or IVT of ANTI-VEGF; better ICGA or OCT-A?. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1689.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Chronic central serous chorioretinopathy (CSCR) may predispose to the development of choroidal neovascularization (CNV) and polypoidal choroidal vasculopathy (PCV) could be present. The aim of the study is to evaluate OCT angiography (OCT-A) and indocyanine green angiography (ICGA) features in patients with Chronic CSCR complicated by PCV, before and after treatments.
Eight eyes of 7 consecutive patients diagnosed as PCV in chronic CSCR on the basis of multimodal imaging were enrolled. Patients were classified in 2 groups: the first group included 4 eyes treated with photodynamic therapy (PDT), the second group included 4 eyes treated with intravitreal injection (IVT) of anti-VEGF (Bevacizumab, Ranibizumab, Aflibercept). OCT-A and ICGA were performed before and after treatment, in order to understand the effect of such therapies on the vascular networks. The fixed follow-up schedule was after 3 months for PDT group and after 1 month for the IVT group.
At the baseline, in the whole series of patients, ICGA was able to detect 100% of the PCV and the data were confirmed by SD OCT analysis. Manual choriocapillaris segmentation of OCT-A showed the presence of PCV in 62 % of the cases. After therapy, the first group (PDT treatment) showed that the polyp lesions were not detectable either by ICGA as well as on OCT-A analysis in 75% of the eyes. In the second group (IVT of anti-VEGF), 75% of the eyes revealed the presence of PCV after treatment on ICGA while on OCT-A in 50% of the eyes was very difficult to detect the presence of the aneurysmatic dilatations characteristic of PCV.
OCT-A can be considered a valuable tool in order to detect the PCV in CSCR but is debatable its use in the follow up of Photodynamic therapy and IVT of anti-VEGF.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.
This PDF is available to Subscribers Only